JP Morgan Healthcare Conference
JP Morgan Healthcare Conference, Day 4: Standard BioTools, Sera Prognostics, OraSure, Geneoscopy
Highlights from the fourth day included preliminary data from Sera Prognostics for its PreTRM blood test.
JP Morgan Healthcare Conference, Day 3: Quanterix, Grail, GeneDx
Highlights from the third day included information about Quanterix's new Simoa One platform, expected to launch at the end of 2025.
At JP Morgan, Myriad Genetics Says Q4 Test Volumes Disappointing, Firm Preps New Launches in 2025
Premium
The firm announced preliminary full-year 2024 revenue estimates that were slightly below expectations.
Although the firm did not provide preliminary financial results for 2024, CEO Chris Smith reaffirmed previous guidance of revenues between $655 million and $667 million.
Executives also provided additional information on the firm's Q4 2024 financial performance.
Jan 15, 2025
Jan 15, 2025
Jan 14, 2025
Jan 14, 2025
Jan 14, 2025